VANCOUVER, BC, Jan. 19, 2021 /PRNewswire/ -
InMed Pharmaceuticals Inc. ( InMed or the Company ) (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ( CBN ), today announced that executives of the Company will speak at the 2021
Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe ( CDP Europe ). CDP Europe will be held virtually from January 19-21, 2021. Michael Woudenberg - Vice President, Chemistry, Manufacturing & Controls, Karen Long - Senior Director, Drug Development, and Prof. Mauro Maccarrone PhD - Scientific Advisor to InMed will all be featured as expert speakers at the event.